U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 0.4% on Tuesday.The Dow traded up 0.39% to 47,731.04 while the NASDAQ rose 0.42% to 23,736.30. The S&P 500 also rose, gaining, 0.07% to 6,879.97.Check This Out: Top 3 Consumer Stocks Which Could Rescue Your Portfolio In Q4Leading and Lagging SectorsInformation technology shares jumped by 0.7% on Tuesday.In trading on Tuesday, real estate stocks fell by 1.6%.Top HeadlinePayPal Holdings Inc. (NASDAQ:PYPL) stock jumped a ...

BREAKING: Stocks Rumble Higher As PayPal, UnitedHealth RallyArcutis Biotherapeutics (ARQT) smashed third-quarter expectations Tuesday and reported its first-ever positive net income, leading Arcutis stock to skyrocket.In late morning trades, Arcutis stock surged more than 24% to 24.49. Shares topped a profit-taking zone after, last month, breaking out of a cup base.The company makes Zoryve, a cream that treats skin conditions like psoriasis and eczema. During the third quarter, Zoryve generated $99.2 millio ...

Arcutis Biotherapeutics (NasdaqGS:ARQT) 2025 Earnings Call October 28, 2025 10:30 AM ET Speaker2Today, and thank you for standing by. Welcome to the Arcutis Biotherapeutics 2025 third quarter financial results and investor day presentation. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To submit questions, please use the question submission field located at the bottom of your webcast interface. Please be advised that ...

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +160.00%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.13, delivering a surprise of +27.78%.Over the last four qu ...

3rd Quarter 2025 Financial Results & Investor Day October 28, 2025 Legal Disclaimers This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Forward- looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financ ...

U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Tuesday.Shares of Wayfair Inc (NYSE:W) rose sharply during Tuesday's session following better-than-expected third-quarter results.Wayfair reported quarterly earnings of 70 cents per share which beat the analyst consensus estimate of 43 cents per share. The company reported quarterly sales of $3.117 billion which beat the analyst consensus estimate of $3.014 billion.Wayfair shares surged 21.8% to $105.40 on Tuesday.Here are some o ...

Product Development and Approvals - ZORYVE cream 0.3% was launched in August 2022 and received FDA approval for expanded indications down to 6 years of age in October 2023[122]. - ZORYVE foam for seborrheic dermatitis was approved by the FDA in December 2023 and became commercially available in January 2024[122]. - A co-promotion agreement with Kowa Pharmaceuticals was established in July 2024 to market ZORYVE in the U.S. until at least July 2029[124]. - The company halted further development of ARQ-255 after completing a Phase 1b study in mid-2025[125]. - The company plans to commence a Phase 1 study of ARQ-234 in the first quarter of 2026 after submitting an IND application in July 2025[126]. Financial Performance - The company reported net losses of $33.5 million and $129.3 million for the nine months ended September 30, 2025 and 2024, respectively, with an accumulated deficit of $1,155.5 million as of September 30, 2025[127]. - Product revenue for ZORYVE cream 0.3% increased by $8.5 million, or 38%, to $30.5 million for the three months ended September 30, 2025, compared to the same period in 2024[146]. - ZORYVE foam revenue surged by $29.5 million, or 146%, reaching $49.8 million for the three months ended September 30, 2025, driven by higher demand and new product launches[148]. - Total product revenue for the three months ended September 30, 2025, was $99.2 million, a 122% increase from $44.8 million in the same period of 2024[146]. - For the nine months ended September 30, 2025, total product revenue reached $244.6 million, a 152% increase from $97.2 million in the same period of 2024[157]. - ZORYVE cream 0.15% revenue increased by $41.3 million, or 1686%, for the nine months ended September 30, 2025, driven by its commercial launch in July 2024[160]. Expenses and Cash Flow - The company expects to incur significant commercialization expenses related to ZORYVE and product candidates, while focusing on clinical development for ARQ-234 and ZORYVE label expansions[128]. - Selling, general and administrative expenses are anticipated to increase as the company continues to commercialize ZORYVE and support operations[140]. - Research and development expenses slightly increased by $0.1 million, or 1%, totaling $19.6 million for the three months ended September 30, 2025[152]. - Selling, general and administrative expenses rose by $3.6 million, or 6%, to $63.5 million for the three months ended September 30, 2025, primarily due to commercialization efforts[153]. - The company expects research and development expenses to increase in future periods due to ongoing development and clinical studies related to ARQ-234 and ZORYVE life cycle management[165]. - For the nine months ended September 30, 2025, net cash used in operating activities was $31.8 million, compared to $111.4 million for the same period in 2024[185][187]. - During the nine months ended September 30, 2025, net cash provided by investing activities was $3.9 million, primarily from maturities of marketable securities totaling $172.4 million[188]. Debt and Interest Rates - As of September 30, 2025, the aggregate principal amount outstanding under the Loan Agreement was $100.0 million[174]. - The company made a 2024 Partial Prepayment of $100.0 million, reducing the outstanding principal under the Loan Agreement and incurring a prepayment penalty of $1.0 million[175]. - The applicable interest rate after the 2024 Partial Prepayment is 5.95% plus the greater of 2.50% or the one-month Secured Overnight Financing Rate (SOFR)[176]. - The company has $100.0 million outstanding under its Loan Agreement, with a floating interest rate of 5.95% plus the greater of 2.50% or the one-month SOFR[195]. - A 100 basis point increase in interest rates would result in approximately $1.0 million of additional annual interest expense for the company[195]. - The maturity date of the Loan Agreement is August 1, 2029, following the 2024 Partial Prepayment[175]. Cash and Securities - As of September 30, 2025, the company had cash, cash equivalents, restricted cash, and marketable securities totaling $191.4 million[127]. - As of September 30, 2025, the company had cash and cash equivalents of $47.1 million, restricted cash of $0.3 million, and marketable securities totaling $143.9 million[194]. Foreign Currency and Risk Management - The company is exposed to foreign currency exchange risk due to its Canadian subsidiary operating in Canadian dollars, with cash balances of $6.4 million in Canadian dollars as of September 30, 2025[196]. - The company does not currently engage in hedging transactions for interest rate or foreign currency risks[195][196]. - A hypothetical 10% change in foreign exchange rates would not have a material impact on the company's condensed consolidated financial statements[196]. - An immediate change in interest rates of 100 basis points would not materially affect the fair value of the company's investment portfolio due to its low risk profile[194].

Financial Performance - Q3 2025 net product revenue for ZORYVE was $99.2 million, a 122% increase compared to Q3 2024, and a 22% increase compared to Q2 2025[4] - ZORYVE net product sales for Q3 2025 were $99.2 million, driven by increasing demand and improved gross-to-net pricing[8] - Product revenue for Q3 2025 reached $99.219 million, a significant increase from $44.755 million in Q3 2024, representing a growth of 121%[27] - Total revenues for the nine months ended September 2025 were $246.569 million, compared to $125.182 million for the same period in 2024, marking a 97% increase[27] - Net income for Q3 2025 was $7.4 million, compared to a net loss of $41.5 million in Q3 2024[16] - Net income for Q3 2025 was $7.410 million, a recovery from a net loss of $41.537 million in Q3 2024[27] - Basic earnings per share for Q3 2025 were $0.06, compared to a loss of $0.33 per share in Q3 2024[27] Expenses - Research and development expenses for Q3 2025 were $19.6 million, consistent with the previous year[14] - Selling, general, and administrative expenses for Q3 2025 were $62.4 million, an increase from $58.8 million in Q3 2024[15] - Operating expenses for Q3 2025 totaled $90.693 million, up from $83.821 million in Q3 2024, reflecting an increase of 8%[27] - Research and development expenses for the nine months ended September 2025 were $56.600 million, down from $61.940 million in the same period of 2024, a decrease of 9%[27] - Selling, general, and administrative expenses increased to $62.404 million in Q3 2025 from $58.817 million in Q3 2024, an increase of 4%[27] - Interest expense for the nine months ended September 2025 was $9.082 million, down from $21.617 million in the same period of 2024, a reduction of 58%[27] - The company reported other income of $2.035 million in Q3 2025, compared to $4.182 million in Q3 2024, a decrease of 51%[27] Product Development - ZORYVE cream 0.05% received FDA approval for treating atopic dermatitis in children as young as 2 years old in October 2025[4] - The company provided initial 2026 full year net product sales guidance of $455–$470 million[17] - ZORYVE is projected to achieve peak sales of $2.6–$3.5 billion annually across current and potential future indications[7] - The company is preparing to initiate a Phase 1 study of ARQ-234, a potential biologic treatment for atopic dermatitis[9] Cash and Securities - Cash, cash equivalents, and marketable securities totaled $191.4 million as of September 30, 2025, down from $228.6 million at the end of 2024[16] - The weighted-average diluted shares used in computing earnings per share for Q3 2025 were 132,885 thousand, unchanged from Q3 2024[27]

Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and Drug Administration (FDA) approval for the treatment of atopic dermatitis in children down to 2 years of age in October Company provides initial 2026 full year net product sales guidance of $455–$470 million WESTLAKE VILLAGE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) ...

New data from Phase 3 studies show once-daily ZORYVE cream helped reduce sleep disruptions in individuals with atopic dermatitis aged ≥2 yearsNew long-term data demonstrate that ZORYVE cream was well-tolerated and provided continued disease control for individuals who switched to twice-weekly treatment WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation ...